Modules
Maple Pathology Labs, LLC
Customer 43803
- Account Classification
- End-User Laboratory
- Classification Confidence
- High
- Sites
- HQ | 7ebca0c477d4b295c6001f51be0d529c993eb16142a53e2795e32a8c1e57cb8d
- Assigned Reps
- Marcus Feldman
- Website
- —
- Active Opportunity Count
- 21
- Published Count
- 11
- Revenue Base
- 29524.230000000003
- Known GPBase
- 8486.420000000002
- Analyzer Platforms
- Roche | ROCHE-E411
- Product Groups
- Roche | ROCHE-E411
- Recommended Contact
- Carly Isakov
- Backup Contact
- Oscar Quezada | | oscar.quezada@maplepathologylabsllc.com | (714) 340-4690
- Last Meaningful Activity
- 2026-07-20
- Customer Memory
- AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach. Verified transaction fact: platform/product group signal is Roche. Verified item fact: storage requirement Fridge. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach. Verified item fact: storage requirement Fridge. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach.
- Evidence References
- Candidate CAND-d18e7a6f1284bce4ef074261dfc81586e65a41a3abac1851f0fc4257728e4b67 | Customer 43803 | Candidate CAND-e3e930e5c8a2450d772a93c0a5d0f41de921bdc099c9310cda819e3ad4b06196 | Customer 43803 | Order 51086 | Item 16993 | Candidate CAND-7a031c99cc88a1d5cceb10aef288244e4cdd3f363f7725bf69b69b756e35f9ec | Customer 43803 | Quote 28399 | Order 49147 | Item 17155 | Candidate CAND-45d1f0819ede4bef169d3f579e3c7267382d401479a443d1213ec3c721d9636a | Customer 43803 | Order 51086 | Item 17095 | Candidate CAND-fb045f28aeb979f87f69f60310634bdbfcd44aee249cf5a3a1462f5dbc32f52d | Customer 43803 | Order 50266 | Item 17094 | Candidate CAND-c222f6add299c1a62bd33840b45558bd5c0bad07bc3fabcbf091242b92dd1161 | Customer 43803 | Order 50065 | Item 16990 | Candidate CAND-93229955103606580c4fc080bac68a68b3b00056bcbe2ce4e95cd46ac038bb42 | Customer 43803 | Order 50065 | Item 16988 | Candidate CAND-b9e227641dcf66e847629e52935d8d2e09a58a3f317082b52afdb2e13486d891 | Customer 43803 | Order 50065 | Item 16984 | Candidate CAND-303e2c35e0ecc798a8ab71fcaef6bef3c793d94d35c1e88f490e97bd4f041d29 | Customer 43803 | Order 50065 | Item 16985 | Candidate CAND-7e64958bae77473cb0f63f3514ee89828c719c6412994f444abaca03e84c02d2 | Customer 43803 | Order 50368 | Item 16983 | Candidate CAND-210f57e58300783fd28ad28a80f3254b0df485033fd6a0aea8e1661e94a14a57 | Customer 43803 | Order 50368 | Item 16991 | Candidate CAND-896f87f62cca4cc73ced5cbb9c4c068a3a951271039dad112ed346539a7335db | Customer 43803 | Order 50368 | Item 13851
Opportunities (30)
| Source Sheet | Report Run ID | Candidate ID | Opportunity ID | Opportunity Series ID | Final Disposition | Assigned Rep | Territory Rep | Source Rep | Customer | Customer ID | Site | City | State | Region | Account Classification | Classification Confidence | Analyzer Platform | Product Group | SKU | Item Description | Quote Doc No | Order Doc No | Deterministic Signal | Revenue Low | Revenue Base | Revenue High | GP Low | GP Base | GP High | Priority Score | Confidence | Open Order | Open Quote | Suppression Status | Next Best Action | Evidence Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Account Risk | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-d18e7a6f1284bce4ef074261dfc81586e65a41a3abac1851f0fc4257728e4b67 | OPP-531868d308e4d35e668015311421b6b7368d57511042c56ed4f0dd203865899a | SER-57dc7acfca95f9247b66476cdad520ecbbcfc4881e7f14fcdcab75fc4a30a988 | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | — | — | — | — | — | — | Revenue and Gross-Profit Decline; 6 independent signals; trailing 90-day revenue $0.00 versus $6586.38; trailing 180-day revenue $6586.38 versus $52563.01; 115 days beyond expected account order date. | 11494.16 | 22988.32 | 34482.47 | 3284.05 | 6568.09 | 9852.14 | 94.51 | High | False | True | — | CALL | Candidate CAND-d18e7a6f1284bce4ef074261dfc81586e65a41a3abac1851f0fc4257728e4b67 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-e3e930e5c8a2450d772a93c0a5d0f41de921bdc099c9310cda819e3ad4b06196 | OPP-7bb1951bbd3ea7cd95c46b64334b45fcf7d89ef664b233fd254ffb04d3e80893 | SER-394e0702e02c4dd3a09f79e9a820a052951af1982313c669cf935ee908e60a8a | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11820567160 | 11820567160 Anti-HBc IgM Elecsys cobas e 100 | — | 51086 | 7 completed purchases over 356 days; median interval 45.0 days; expected reorder 2026-05-04; High Risk by 98 days. | 1267.88 | 1690.5 | 2113.13 | 362.25 | 483 | 603.75 | 75.55 | High | False | False | — | CALL | Candidate CAND-e3e930e5c8a2450d772a93c0a5d0f41de921bdc099c9310cda819e3ad4b06196 | Customer 43803 | Order 51086 | Item 16993 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-45d1f0819ede4bef169d3f579e3c7267382d401479a443d1213ec3c721d9636a | OPP-d9924de5a94a7c26bfd9b976afa30ba2620a9f725da5336ab425e50138d24e0a | SER-c110b2f76c4868323e74721ca26d9a928cf018f57a098d9fc42b9af57940f4cc | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11820591160 | Roche Anti-HAV IgM Elecsys Cobas E 100 | — | 51086 | 5 completed purchases over 245 days; median interval 62.5 days; expected reorder 2026-05-15; High Risk by 87 days. | 934.1 | 1245.47 | 1556.83 | 320.27 | 427.02 | 533.78 | 69.38 | Medium | False | False | — | CALL | Candidate CAND-45d1f0819ede4bef169d3f579e3c7267382d401479a443d1213ec3c721d9636a | Customer 43803 | Order 51086 | Item 17095 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-fb045f28aeb979f87f69f60310634bdbfcd44aee249cf5a3a1462f5dbc32f52d | OPP-825a811d2d0da54440bbfd3e77c58f350676efe19993c9fd5025ad7d1cbcaa66 | SER-229063c49903be8912deccdcb5ee51abb1ab5b64b79989ae8b07b3422eb52813 | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 08836981190 | Roche Anti-HCV G2 Elecsys Cobas E 100 V2 | — | 50266 | 4 completed purchases over 192 days; median interval 43.0 days; expected reorder 2026-03-25; High Risk by 138 days. | 1245.46 | 1660.62 | 2075.77 | 427.02 | 569.36 | 711.7 | 68.6 | Medium | False | False | — | CALL | Candidate CAND-fb045f28aeb979f87f69f60310634bdbfcd44aee249cf5a3a1462f5dbc32f52d | Customer 43803 | Order 50266 | Item 17094 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-22466bfea45915cf3dde6e0bacd7525f76dbe1e446dad19f5b4a827bfc64f1c6 | OPP-09760a576081ff21592885c59915c5eeea832375d35d960939c445455aa866f4 | SER-4c6dc7ec6f77a064662dcfcfab48cddcb9d67da56c7a46eb868859fdd79c8a0f | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 8948844160 | HSV-1 IgG Elecsys Cobas E 100 V2 | — | 51086 | 3 completed purchases over 125 days; median interval 62.5 days; expected reorder 2026-05-24; High Risk by 78 days. | 867.68 | 1156.9 | 1446.13 | 247.91 | 330.54 | 413.18 | 67.27 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-22466bfea45915cf3dde6e0bacd7525f76dbe1e446dad19f5b4a827bfc64f1c6 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-c222f6add299c1a62bd33840b45558bd5c0bad07bc3fabcbf091242b92dd1161 | OPP-3a5b6a76e1eb97f412bb69e006a8224af391da4cedbd271e3683dbc760f8ea43 | SER-813f938e8cd0a9d676fc2b085ce4cbcb8482a805e7ff716844ef482c7ce027a7 | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11776193122 | 11776193122 CA 19-9 Elecsys cobas e 100 | — | 50065 | 4 completed purchases over 290 days; median interval 104.0 days; expected reorder 2026-04-25; High Risk by 107 days. | 552.65 | 736.87 | 921.08 | 118.43 | 157.9 | 197.38 | 64.68 | Medium | False | False | — | CALL | Candidate CAND-c222f6add299c1a62bd33840b45558bd5c0bad07bc3fabcbf091242b92dd1161 | Customer 43803 | Order 50065 | Item 16990 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-7697142161f18b0f5d5d1cfcb53c4a0224168fa218e97606a20812ea11c3cb94 | OPP-cf34c561060fc2df360d487aab211f197440ee1aa01a89d6085b705adc4022a9 | SER-9284a87643b24bf7ae435c28efe124f1f1c814012b32d28afd59e85bc989a191 | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11731629160 | 11731629160 CEA Elecsys cobas e 100 | — | 49147 | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | 451.56 | 602.08 | 752.6 | 96.77 | 129.02 | 161.28 | 62.69 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-7697142161f18b0f5d5d1cfcb53c4a0224168fa218e97606a20812ea11c3cb94 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-2a688d045df6dd453b80aaea81000ae9b94aebbc065f754c7794412ffe77756b | OPP-999099baad1fea7cd0d3e014ac857a064c62c742d867018e3ec2c737054c4969 | SER-06565889a840e634f6fd5f72a465fc177ea528aa834e62240c8f5abdba50c55d | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 08814856160 | Roche HBsAg G2 Elecsys Cobas E 100 V2 | — | 50266 | 3 completed purchases over 101 days; median interval 50.5 days; expected reorder 2026-03-20; High Risk by 143 days. | 592.5 | 790 | 987.5 | 203.15 | 270.86 | 338.58 | 62.07 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-2a688d045df6dd453b80aaea81000ae9b94aebbc065f754c7794412ffe77756b | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-93229955103606580c4fc080bac68a68b3b00056bcbe2ce4e95cd46ac038bb42 | OPP-cedd7e04eedf8f8547fd084a68a6b3790a0aaedcb1890ea6a500ebe634e4db67 | SER-27ad24677d54f53bdefeeb1ce636c05b724d7c900dda0dc66b3a2e570dc8086f | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 09007741190 | 09007741190 T4 Elecsys cobas e 200 V3 | — | 50065 | 4 completed purchases over 290 days; median interval 104.0 days; expected reorder 2026-04-25; High Risk by 107 days. | 204.76 | 273.01 | 341.27 | 43.88 | 58.5 | 73.13 | 60.6 | Medium | False | False | — | CALL | Candidate CAND-93229955103606580c4fc080bac68a68b3b00056bcbe2ce4e95cd46ac038bb42 | Customer 43803 | Order 50065 | Item 16988 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-37f1eea3c07faa9cfd639655283f3ff98798ce4da9e489e219abc8eb8447dad1 | OPP-1c84910a35203f422c9ca60164b6384835d3785d9d7fffbb367714b51bfd5812 | SER-a76a47fffc110df245d156f14fb1cf1e428749658a5f26caed00dc16e26c622d | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 07092539190 | 07092539190 Progesterone III Gen 100 Test | — | 49147 | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | 248.65 | 331.53 | 414.42 | 53.28 | 71.04 | 88.8 | 60.25 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-37f1eea3c07faa9cfd639655283f3ff98798ce4da9e489e219abc8eb8447dad1 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-b9e227641dcf66e847629e52935d8d2e09a58a3f317082b52afdb2e13486d891 | OPP-1fc6cd5f6631be5a1575aabc14ffab55b642a7cba7b86ccceb176d8728e5a2eb | SER-13a76e882d73c875f2dae4a106f166c38ab331cfb2d791645661577b2562f920 | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 03271749160 | 03271749160 HCG+beta Elecsys cobas e 100 V2 | — | 50065 | 4 completed purchases over 290 days; median interval 104.0 days; expected reorder 2026-04-25; High Risk by 107 days. | 155.12 | 206.83 | 258.53 | 33.24 | 44.32 | 55.4 | 59.85 | Medium | False | False | — | CALL | Candidate CAND-b9e227641dcf66e847629e52935d8d2e09a58a3f317082b52afdb2e13486d891 | Customer 43803 | Order 50065 | Item 16984 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-705e67c5d697af1dac9a3450caed4401d7f50e3c5b52108fa5cc8b37be8c1232 | OPP-bab0c8e7dd38e571e6664380b4ad79e0a4c89a8c26f89e7cc0f3d38979791f1d | SER-5860c2cee687acec483d091c82f2c1126f0877b13637d94de2cc86d8d5734fe1 | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 09007725190 | 09007725190 T3 Elecsys cobas e 200 V2 | — | 49147 | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | 204.76 | 273.01 | 341.27 | 43.88 | 58.5 | 73.13 | 59.63 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-705e67c5d697af1dac9a3450caed4401d7f50e3c5b52108fa5cc8b37be8c1232 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-303e2c35e0ecc798a8ab71fcaef6bef3c793d94d35c1e88f490e97bd4f041d29 | OPP-c7e1a6ed87ea4cd3abb1dd43955565561baa36c7dd2f6e4203b3a208518df8c3 | SER-2cf0657fbc6d3fc5d417df66dd25dedfb0b62a4d39743e0460deab1c00cdb77d | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 06687733160 | 06687733160 Cortisol G2 Elecsys cobas e 100 | — | 50065 | 4 completed purchases over 290 days; median interval 104.0 days; expected reorder 2026-04-25; High Risk by 107 days. | 132.73 | 176.97 | 221.22 | 28.44 | 37.92 | 47.4 | 59.5 | Medium | False | False | — | CALL | Candidate CAND-303e2c35e0ecc798a8ab71fcaef6bef3c793d94d35c1e88f490e97bd4f041d29 | Customer 43803 | Order 50065 | Item 16985 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-210f57e58300783fd28ad28a80f3254b0df485033fd6a0aea8e1661e94a14a57 | OPP-83a9122c5b1dce89604e6b17c07ff6a13eaa9e503dd0c16c3bf7e4d8d03256af | SER-6d478bc20d8c8e1e9eb20f2eeaa52a326ae92f4cffc3000f4a261fd51698a69a | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11776215122 | 11776215122 CA 19-9 CS Elecsys | — | 50368 | 4 completed purchases over 309 days; median interval 104.0 days; expected reorder 2026-05-17; High Risk by 85 days. | 136.41 | 181.88 | 227.35 | 35.08 | 46.77 | 58.46 | 59.38 | Medium | False | False | — | CALL | Candidate CAND-210f57e58300783fd28ad28a80f3254b0df485033fd6a0aea8e1661e94a14a57 | Customer 43803 | Order 50368 | Item 16991 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-7e64958bae77473cb0f63f3514ee89828c719c6412994f444abaca03e84c02d2 | OPP-1aa9ab899cbce4f5dd6d3402e928c71c8fe2920befc55ddd5b9ffd2e3d5d03d9 | SER-3cccb82f5a407863793a2df51955493218326ca3646c545ab2f392cf333b041b | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 03045846122 | 03045846122 CA 15-3 G2 CS Elecsys | — | 50368 | 4 completed purchases over 309 days; median interval 104.0 days; expected reorder 2026-05-17; High Risk by 85 days. | 136.41 | 181.88 | 227.35 | 35.08 | 46.77 | 58.46 | 59.38 | Medium | False | False | — | CALL | Candidate CAND-7e64958bae77473cb0f63f3514ee89828c719c6412994f444abaca03e84c02d2 | Customer 43803 | Order 50368 | Item 16983 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-896f87f62cca4cc73ced5cbb9c4c068a3a951271039dad112ed346539a7335db | OPP-3f83fae7d850143097a45f88a6c507385227d158da682d9deaa87aee752e3860 | SER-5ae8da708a0c59b0ba555561676e9b404283589992bb9156357bb80f5a029f18 | Published | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11731548122 | 11731548122 T3 Calibrator Set 2 x 2 x 1mL | — | 50368 | 4 completed purchases over 309 days; median interval 104.0 days; expected reorder 2026-05-17; High Risk by 85 days. | 136.41 | 181.88 | 227.35 | 35.08 | 46.77 | 58.46 | 59.38 | Medium | False | False | — | CALL | Candidate CAND-896f87f62cca4cc73ced5cbb9c4c068a3a951271039dad112ed346539a7335db | Customer 43803 | Order 50368 | Item 13851 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-d8023e073c89c3e5b4f4f6010563f9622d81c67cb2d436b1dc689b6a7668f9db | OPP-49802943a3f82119a4b744b51c5c8ccb92929598f9e95c8f7aae552a7a1bf702 | SER-09f74040dbcda334d3783e9588f3d38ec660249b5c76d82747cfcf2d52be1359 | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 08932352190 | 08932352190 FSH Elecsys cobas e 100 V2 | — | 49147 | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | 132.73 | 176.97 | 221.22 | 28.44 | 37.92 | 47.4 | 58.53 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-d8023e073c89c3e5b4f4f6010563f9622d81c67cb2d436b1dc689b6a7668f9db | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-46b3687ba3de9feb81d8a89dd50eb43835ade5720b9021523ce51d381f3b4e10 | OPP-5fd1f95069e33f43203a1cce1f813c10474191e0bb8bd9617ada1d68da428e4a | SER-d56f0d167cbe0fa9e579739a5f3d74f11f502fffde763aaf9f172cbb4f295ad7 | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 11732234122 | 11732234122 LH E411 100 T | — | 49147 | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | 130.09 | 173.45 | 216.82 | 27.88 | 37.17 | 46.46 | 58.49 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-46b3687ba3de9feb81d8a89dd50eb43835ade5720b9021523ce51d381f3b4e10 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-33bbd9fc2352d959055c3fa99c13b7052db144b648ee43887bc0f00d56be77e6 | OPP-f7d6e9d8c1100364c40d6c5ae4b67de1f5c18dddfccb8f0ab0fe8983e1a4eed6 | SER-81900a52230054bcb3a3eccbb9027905d2548bd351060e9a043bf9a060a5fdd4 | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | ROCHE-E411 | ROCHE-E411 | 08429324160 | 08429324160 Thyroid Stimulating (TSH) 200 Test | — | 50708 | 3 completed purchases over 131 days; median interval 65.5 days; expected reorder 2026-05-01; High Risk by 101 days. | 297.76 | 397.02 | 496.27 | 102.09 | 136.12 | 170.15 | 58.04 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-33bbd9fc2352d959055c3fa99c13b7052db144b648ee43887bc0f00d56be77e6 | Customer 43803 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-ebaf25ad8406dc13558abb7cc0a301f44d7eda1a299a406446975ffec0d61366 | OPP-eedd6eba9baac74f472fcce3b5b3e783276f1a7cf6718d577b62cd0573d32d44 | SER-ad715d2e81fab07d550d97c47dabd8a53f2e523e4f4f0fae9b38a08bc4b7178f | Needs Validation | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | HQ | Irvine | CA | Southwest | End-User Laboratory | High | Roche | Roche | 04687876160 | 11876309160 HBsAg PC Elecsys | — | 50266 | 3 completed purchases over 303 days; median interval 151.5 days; expected reorder 2026-06-29; Overdue by 42 days. | 127.75 | 170.33 | 212.92 | 43.8 | 58.4 | 73 | 50.33 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-ebaf25ad8406dc13558abb7cc0a301f44d7eda1a299a406446975ffec0d61366 | Customer 43803 |
| Quote Leakage | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-7a031c99cc88a1d5cceb10aef288244e4cdd3f363f7725bf69b69b756e35f9ec | OPP-c85c228f3662b49a3f80d71e39b7c9ee9f9629477e8179f71b12f4246e2294f0 | SER-3c6d81a2f8d9ac2238e8b7d20b79f112148d4e3b72f4953192254fc889b91e2d | Suppressed by Counter-Evidence | **** | **** | **** | Maple Pathology Labs, LLC | 43803 | — | Irvine | CA | Southwest | End-User Laboratory | High | — | Roche | 09038078160 | Roche Vitamin D Total G3 Elecsys Cobas E100 | 28399 | 49147 | Partial Line Conversion on quote 28399; quote age 270 days; last modified 265 days ago; quoted value $15377.95; converted line value $9782.72; unconverted line value $5595.23. | 1818.45 | 3636.9 | 5455.35 | — | — | — | 76.75 | Low | False | False | Closed Won / Terminal Quote | NO_ACTION | Candidate CAND-7a031c99cc88a1d5cceb10aef288244e4cdd3f363f7725bf69b69b756e35f9ec | Customer 43803 | Quote 28399 | Order 49147 | Item 17155 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-22466bfea45915cf3dde6e0bacd7525f76dbe1e446dad19f5b4a827bfc64f1c6 | OPP-09760a576081ff21592885c59915c5eeea832375d35d960939c445455aa866f4 | SER-4c6dc7ec6f77a064662dcfcfab48cddcb9d67da56c7a46eb868859fdd79c8a0f | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 125 days; median interval 62.5 days; expected reorder 2026-05-24; High Risk by 78 days. | — | 1156.9 | — | — | 330.54 | — | 67.27 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-22466bfea45915cf3dde6e0bacd7525f76dbe1e446dad19f5b4a827bfc64f1c6 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-7697142161f18b0f5d5d1cfcb53c4a0224168fa218e97606a20812ea11c3cb94 | OPP-cf34c561060fc2df360d487aab211f197440ee1aa01a89d6085b705adc4022a9 | SER-9284a87643b24bf7ae435c28efe124f1f1c814012b32d28afd59e85bc989a191 | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | — | 602.08 | — | — | 129.02 | — | 62.69 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-7697142161f18b0f5d5d1cfcb53c4a0224168fa218e97606a20812ea11c3cb94 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-2a688d045df6dd453b80aaea81000ae9b94aebbc065f754c7794412ffe77756b | OPP-999099baad1fea7cd0d3e014ac857a064c62c742d867018e3ec2c737054c4969 | SER-06565889a840e634f6fd5f72a465fc177ea528aa834e62240c8f5abdba50c55d | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 101 days; median interval 50.5 days; expected reorder 2026-03-20; High Risk by 143 days. | — | 790 | — | — | 270.86 | — | 62.07 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-2a688d045df6dd453b80aaea81000ae9b94aebbc065f754c7794412ffe77756b | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-37f1eea3c07faa9cfd639655283f3ff98798ce4da9e489e219abc8eb8447dad1 | OPP-1c84910a35203f422c9ca60164b6384835d3785d9d7fffbb367714b51bfd5812 | SER-a76a47fffc110df245d156f14fb1cf1e428749658a5f26caed00dc16e26c622d | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | — | 331.53 | — | — | 71.04 | — | 60.25 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-37f1eea3c07faa9cfd639655283f3ff98798ce4da9e489e219abc8eb8447dad1 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-705e67c5d697af1dac9a3450caed4401d7f50e3c5b52108fa5cc8b37be8c1232 | OPP-bab0c8e7dd38e571e6664380b4ad79e0a4c89a8c26f89e7cc0f3d38979791f1d | SER-5860c2cee687acec483d091c82f2c1126f0877b13637d94de2cc86d8d5734fe1 | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | — | 273.01 | — | — | 58.5 | — | 59.63 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-705e67c5d697af1dac9a3450caed4401d7f50e3c5b52108fa5cc8b37be8c1232 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-d8023e073c89c3e5b4f4f6010563f9622d81c67cb2d436b1dc689b6a7668f9db | OPP-49802943a3f82119a4b744b51c5c8ccb92929598f9e95c8f7aae552a7a1bf702 | SER-09f74040dbcda334d3783e9588f3d38ec660249b5c76d82747cfcf2d52be1359 | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | — | 176.97 | — | — | 37.92 | — | 58.53 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-d8023e073c89c3e5b4f4f6010563f9622d81c67cb2d436b1dc689b6a7668f9db | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-46b3687ba3de9feb81d8a89dd50eb43835ade5720b9021523ce51d381f3b4e10 | OPP-5fd1f95069e33f43203a1cce1f813c10474191e0bb8bd9617ada1d68da428e4a | SER-d56f0d167cbe0fa9e579739a5f3d74f11f502fffde763aaf9f172cbb4f295ad7 | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 231 days; median interval 115.5 days; expected reorder 2026-03-13; High Risk by 150 days. | — | 173.45 | — | — | 37.17 | — | 58.49 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-46b3687ba3de9feb81d8a89dd50eb43835ade5720b9021523ce51d381f3b4e10 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-33bbd9fc2352d959055c3fa99c13b7052db144b648ee43887bc0f00d56be77e6 | OPP-f7d6e9d8c1100364c40d6c5ae4b67de1f5c18dddfccb8f0ab0fe8983e1a4eed6 | SER-81900a52230054bcb3a3eccbb9027905d2548bd351060e9a043bf9a060a5fdd4 | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | ROCHE-E411 | — | — | — | — | — | 3 completed purchases over 131 days; median interval 65.5 days; expected reorder 2026-05-01; High Risk by 101 days. | — | 397.02 | — | — | 136.12 | — | 58.04 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-33bbd9fc2352d959055c3fa99c13b7052db144b648ee43887bc0f00d56be77e6 | Customer 43803 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-ebaf25ad8406dc13558abb7cc0a301f44d7eda1a299a406446975ffec0d61366 | OPP-eedd6eba9baac74f472fcce3b5b3e783276f1a7cf6718d577b62cd0573d32d44 | SER-ad715d2e81fab07d550d97c47dabd8a53f2e523e4f4f0fae9b38a08bc4b7178f | — | **** | — | — | Maple Pathology Labs, LLC | 43803 | HQ | — | CA | — | — | — | Roche | — | — | — | — | — | 3 completed purchases over 303 days; median interval 151.5 days; expected reorder 2026-06-29; Overdue by 42 days. | — | 170.33 | — | — | 58.4 | — | 50.33 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-ebaf25ad8406dc13558abb7cc0a301f44d7eda1a299a406446975ffec0d61366 | Customer 43803 |